Biotechnology company Entos Pharmaceuticals Inc reported on Wednesday the signing of a research, development and collaboration agreement with a biopharmaceutical partner to develop novel therapeutic compounds targeting autoimmune and inflammatory diseases.
The companies will collaborate on the formulation and screening of candidates using Entos' Fusogenix non-viral delivery platform for nucleic acid therapies. Fusogenix uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi and CRISPR.
This R&D agreement provides the partner company with the option to exclusively license the candidates developed from Entos for further development and commercialisation.
As part of the agreement, Entos receives research funding and is eligible for option exercise fees and research, development, regulatory and sales milestone payments of up to USD109m from the partner.
In addition, the partner will pay Entos undisclosed royalties on sales of products resulting from the collaboration.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins